Shareholders support Management proposals at SYGNIS’ AGM with large majority
Madrid, Spain and Heidelberg, Germany, 10 July 2015 – At the Annual General Meeting (AGM) of SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) held on 8 July 2015 shareholders representing 59 percent of the capital approved all proposals of the Management with an large majority. Main decisions were related to the discharge of the members of the Supervisory and the Management Board for the past fiscal year, the creation of new authorized capital, as well as changes due to the authorizing the Management Board to issue convertible bonds excluding subscription rights.
At the Annual General Meeting, Pilar de la Huerta, CEO and CFO of SYGNIS, highlighted financial and strategic achievements during fiscal year 2014, including the successful implementation of the new product and commercialization strategy, the launch of the first own product line based on the SYGNIS’ proprietary TruePrimeTM technology for or primer- free whole genome amplification and the very successful expansion of the Company’s sales and marketing network by signing the first distribution agreements. For the current year, de la Huerta expects the development of further products in the field of DNA amplification and sequencing and the strengthening of SYGNIS’ position especially in the market for Next Generation Sequencing (NGS).
You will find further information about our AGM and the detailed voting results on our website: http://www.sygnis.com in the Investor Relations section.
For further information please contact:
Pilar de la Huerta
Phone: +34 91 192 36 50
MC Services AG
Phone: +49 89 210228 30